Do you want to read an article? Please log in or register.
XALOC-1: Clinical remission over 2-years with benralizumab in severe eosinophilic asthma
Asthma
COMMENTED
Related content
RECOMMENDED
Asthma
Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Quarato CMI, Tondo P, Lacedonia D, Soccio P, Pescatore D, Baccellieri ML, Lepore G, Foschino Barbaro MP, Scioscia G
doi: 10.3390/jcm14062075
RECOMMENDED
Asthma
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Wechsler ME, Brusselle G, Virchow JC, Bourdin A, Kostikas K, Llanos JP, Roseti SL, Ambrose CS, Hunter G, Jackson DJ, Castro M, Lugogo N, Pavord ID, Martin N, Brightling CE
doi: 10.1183/13993003.00316-2024
Asthma
Early and Sustained Clinical Benefits of Benralizumab in Severe Eosinophilic Asthma: Findings from the ORBE II Study
J Clin Med
Ausín P, Navarrete-Rouco ME, Carazo L, Sanchez-Trincado JL, Luzon E, Nuevo J, Santín M, Sánchez J, Padilla-Galo A
doi: 10.3390/jcm14093011
AsthmaRespiratory Tract Infection
Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register
Respir Med
Hansen S, Håkansson KEJ, Soendergaard MB, Bjerrum AS, Schmid JM, Johansson SL, Rasmussen LM, Johnsen CR, von Bülow A, Bonnesen B, Krogh NS, Hilberg O, Dongo L, Vijdea R, Ulrik CS, Porsbjerg C
doi: 10.1016/j.rmed.2025.108203
RECOMMENDED
Further Publications
Dupilumab 200 mg was efficacious in children (6-11 years) with moderate-to-severe asthma for up to 2 years: EXCURSION open-label extension study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Pediatr Pulmonol
Phipatanakul W, Vogelberg C, Bacharier LB, Dell S, Altincatal A, Gall R, Ledanois O, Sacks H, Jacob-Nara JA, Deniz Y, Rowe PJ
doi: 10.1002/ppul.27167
RECOMMENDED
Asthma
Early and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Stolz D, Schuoler C, Charbonnier F, Bridevaux PO, Jandus P, Leuppi JD, Pavlov N, Piecyk A, Rothe T
doi: 10.2147/JAA.S495867
ERS 2024
Asthma
BEHAVE: Benralizumab reduces exacerbations and improves asthma control in real-world patients with severe asthma
Asthma
Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)
Allergy Asthma Immunol Res
Park SY, Lee D, Kim JH, Lee Y, Ban GY, Sim DW, Kwon JW, Kim SR, Song WJ, Park HW, Chang YS, Koh YI, Lee BJ, Park HS, Cho YS, Kim SH
doi: 10.4168/aair.2025.17.3.384
RECOMMENDED
Asthma
Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Chiner E, Murcia M, Boira I, Bernabeu MÁ, Esteban V, Martínez-Moragón E
doi: 10.3390/jcm13144247